RNXT
RenovoRx Inc

3,240
Mkt Cap
$35.8M
Volume
1.00
52W High
$1.69
52W Low
$0.7006
PE Ratio
-2.79
RNXT Fundamentals
Price
$0.9929
Prev Close
$0.9769
Open
$1.00
50D MA
$1.02
Beta
0.92
Avg. Volume
378,817.37
EPS (Annual)
-$0.3958
P/B
4.50
Rev/Employee
$4,300.00
Loading...
Loading...
News
all
press releases
RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates
RenovoRx (RNXT) delivered earnings and revenue surprises of 0.00% and -35.12%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·29d ago
News Placeholder
More News
News Placeholder
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation PR Newswire VANCOUVER, BC, Oct. 17, 2025...
PR Newswire·2mo ago
News Placeholder
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwrights 27th Annual Global Investment Conference in New York City, September 8-10, 2025
RenovoRx, Inc. (RenovoRx or the Company) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared...
Business Wire·4mo ago
News Placeholder
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates
RenovoRx (RNXT) delivered earnings and revenue surprises of 0.00% and +22.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates
Zacks·7mo ago

Latest RNXT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.